ArticleJournal of applied clinical medical physics2026
Dynamic Proton arc therapy for paediatric parameningeal rhabdomyosarcoma.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundParameningeal rhabdomyosarcomas (PM-RMS) are pediatric tumors with a high risk of local failure and severe toxicity. Intensity modulated proton therapy (IMPT) offers improved healthy tissue sparing compared to conventional photon-based radiotherapy, and proton arc therapy (PAT) might offer further improvement in healthy tissue sparing for these patients, thus emphasizing the need for systematic studies specifically focusing on PM-RMS patients. Additionally, the relative biological effectiveness (RBE) of protons is known to vary with linear energy transfer (LET). PURPOSE: The aim of this study was to investigate the potential of LET-optimized PAT for PM-RMS treatment.
methodsVolumetric modulated arc therapy (VMAT) plans, IMPT and PAT plans, both with and without LET optimization were made for 13 PM-RMS patients using Raystation version 2023B. The plans were evaluated based on the achievement of clinical goals, homogeneity index, delivery time, robustness, LET and variable RBE-weighted dose within the target and selected OARs.
resultsLET optimization increased the mean LET in the target from 2.5 keV/µm [2.1, 2.8] to 3.4 keV/µm [2.7, 4.1] for IMPT and from 2.8 keV/µm [2.5, 3.1] to 3.4 keV/µm [2.7, 4.0] for PAT with minor changes in dose distributions. Target coverage and OAR doses were comparable between IMPT and PAT, while both had an expected improvement in OAR sparing compared to VMAT. Delivery times were 134.5 [95.3, 203.7] seconds for the IMPT plans and 197.4 [138.9, 244.6] seconds for the PAT plans before LET optimization, and were for both modalities reduced by around 2-5 seconds after LET optimization.
conclusionsThe dose distribution was similar across PAT and IMPT in this study, and superior compared to VMAT. LET optimization in the proton plans achieved LET improvements in both target and OARs without compromising dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.